Isavuconazole is one of 25 small molecule programs targeting Mucormycosis. It is currently in Phase 1.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
26 competitors in Acute Myeloid Leukemia (AML)
Venclexta
Cytosar
Vidaza
Cerubidine
Granulocyte Colony-Stimulating Factor
Lisaftoclax
AG-120
Mitoxantrone Hydrochloride Liposome
Niclocide
Jakafi
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources